# Genascence Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genascence

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.genascence.com
- Total disclosed funding: $11M
- Latest round: Series A (Jan 7, 2022)
- Investors on record: 4

## About

Based in California, US, and founded in 2017, Genascence Corporation operates as a gene therapy company. The company was founded by its CEO Thomas W. Chalberg, CSO Annahita Keravala, Christopher Evans, Paul Robbins, and Steven Ghivizzani. In January 2022, Genascence Corporation raised USD 10.5 million in Series A funding led by Pacira Pharmaceuticals, Inc., DeepWork Capital, the University of Florida Research Foundation, and Polymerase Capital. The Series A funding values Genascence Corporation at USD 72.3 million post-money,

Genascence manufactures and develops gene therapies and biological medicines for the treatment of genetic diseases, including musculoskeletal diseases. The company’s product line includes GNSC-001, which is a genetic medicine that is used for the treatment of osteoarthritis (OA), a knee joint disease.

The company plans to use the funds raised in January 2022 to develop the clinical and innovative aspects of the new medication, GNSC-001 injection.

## Funding rounds

- Series A, Jan 7, 2022, $11M — University of Florida Research Foundation, Pacira Pharmaceuticals, Inc., DeepWork Capital, Polymerase Capital

## Investors

- University of Florida Research Foundation — Series A
- Pacira Pharmaceuticals, Inc. — Series A
- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series A
- Polymerase Capital (https://capitalatlas.ai/funds/polymerase-capital) — Series A